|Frank H. Ebetino
Research Professor, Chemistry Department, University of Rochester President, BioVinc, Pasadena, United States.
|Dr. Ebetino has been involved in medicinal chemistry research for over 35 years. He continues research efforts with collaborators internationally, and he has maintained a strong interest in tissue selective drug and diagnostics design. His specific interests include new bone targeted bisphosphonate conjugates as therapeutics, and the development of novel PET scanning probes and fluorescent diagnostic agents, for bone related diseases. He was part of the Procter & Gamble team that discovered and developed the bisphosphonate drug Actonel® for osteoporosis and more recently established and led the Drug Discovery Department at Warner Chilcott Pharmaceuticals as Director. His publications span a variety of therapeutic areas including Osteoporosis, Arthritis, Obesity, Infectious Diseases, Gastrointestinal Disease, and Cancer. Besides his current role as President, of the biotech company BioVinc, LLC, he also continues his work as Research Professor at the University of Rochester. He has held several adjunct academic roles including Visiting Scholar at the University of Southern California, and is currently an Academic Visitor at the Structural Genomics Consortium, University of Oxford, UK and a Visiting Research Professor at Queen?s University, Belfast. Dr. Ebetino is a long-standing member of the American Society for Bone and Mineral Research and the American Chemical Society.|
|Medicinal chemistry and drug design, including bisphosphonates and bone targeted drugs for arthritis, infectious bone disease, and cancer. Receptor agonists/antagonists, and epigenetic enzyme inhibitors.|
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2017 All rights reserved. iMedPub Last revised : October 16, 2017